Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q1 2018 call → NOWe need to answer YES or NO based on the transcript. The question asks: does management describe that the company's successive engagements of the same kind are coming in at progressively larger size? That is, are the deals, orders, contracts, projects, customers, sites, or programs it is landing now individually bigger, broader, or longer than before for the same offering? We need to look for management's own words conveying escalation of unit size, comparison against own past, already real and recurring, and early stage. Scan the transcript. Management discusses three pipeline candidates: TransCon Growth Hormone, TransCon PTH, TransCon CNP. They talk about clinical trials, enrollment, etc. They mention that for TransCon Growth Hormone, the heiGHt trial exceeded target enrollment with 161 subjects, which strengthens statistical power. That's about enrollment size, not deal size. They talk about fliGHt trial enrolling subjects, and enliGHten extension. No mention of deals or contracts. For TransCon PTH, they completed Phase 1, planning Phase 3. No mention of deal size. For TransCon CNP, they started Phase 1. There is no mention of deals, orders, contracts, customers, or programs getting larger. The company is a biotech, so "engagements" might refer to clinical trials or partnerships? But nothing about that. The question is about "successive engagements of the same kind" coming in at progressively larger size. The transcript does not contain any such description. Management talks about progress in clinical development, but not about the size of deals or contracts. There is no comparison of current vs past deal size. Thus answer NO. We need to be careful: The question is specific to management's own words. There is no such content. So NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.